missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Pinatuzumab Recombinant Monoclonal Antibody

Description
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
pinatuzumab vedotin is under investigation in clinical trial NCT01691898, A Study of pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).
Specifications
Specifications
| Antigen | Pinatuzumab Humanized |
| Anwendungen | ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance |
| Klassifikation | Recombinant Monoclonal |
| Konzentration | 1 mg/mL |
| Konjugat | Unconjugated |
| Zusammensetzung | 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 |
| Gen-Alias | ACD22-VCMMAE; DCDT2980S; FCU2803; RG-7593; RO5541072-000 |
| Wirtsspezies | Human |
| Reinigungsverfahren | Protein A |
| Menge | 100 μg |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?